The 2015 ASRA guidelines categorize procedures depending on their risk: high risk, intermediate risk, and low risk.
These findings highlight an urgent need to produce more evidence on the risks and benefits of off-label antidepressant use.
Peripheral anti-nociceptive effects of Substance P
Finding supports naloxone prescriptions for patients taking opioids for chronic pain
Pharmacogenetic testing yields information that informs how an individual will metabolize medications.
Many adults take five or more medications, often for preventable ills.
Naloxegol functions as a peripherally acting mu-opioid receptor antagonist in tissues such as the gastrointestinal tract, thereby decreasing the constipating effects of opioids.
Epilepsy drug Spritam may be one of many custom-made medicines to come that will use the technology.
For Echo, reducing the therapeutic dose is key to improving compliance and providing both patients and healthcare providers with a more cost-effective therapy.
Clinical and community-based approaches should be used to increase aspirin use among low-use groups.
No indication any particular type of antidepressant carries a greater risk than others.
Clinical Pain Advisor Articles
- Radiofrequency Denervation for Facet Joint Arthropathy-Related Low Back Pain
- Telephone-Based vs In-Person CBT for Chronic Back Pain
- Persistent Pain Linked With Greater Memory Decline & Dementia Probability
- Allodynia and Pericranial Tenderness Highly Prevalent in Pediatric Patients With Migraine
- Reasons Why the Affordable Care Act is Wrongly Blamed for Increased Premiums
- Psychosocial Functioning Distinct From Symptomatic Improvement in Depression
- Ptosis Repair Effective for Relief From Tension-Type Headache
- Acute Pain Management in the Emergency Department With SoluMatrix Indomethacin
- Former Pharma Reps Recruited by Health Insurers to Cut Costs
- Subcutaneous Belimumab Effective on SLE